Pneumonia

Pneumonia – High‑Yield Study Guide for Medical Students

Definition

Pneumonia is an acute infection of the pulmonary parenchyma characterized by inflammation of the alveoli and interstitium, leading to impaired gas exchange and respiratory symptoms. It is typically diagnosed when compatible clinical features are accompanied by new infiltrates on chest imaging not explained by other causes.

Clinically, pneumonia is often classified by the setting and host:

• Community-acquired pneumonia (CAP) – acquired outside healthcare facilities.
• Hospital-acquired pneumonia (HAP) – onset ≥48 hours after hospital admission, not incubating at admission.
• Ventilator-associated pneumonia (VAP) – onset ≥48 hours after endotracheal intubation.
• Aspiration pneumonia – due to inhalation of oropharyngeal or gastric contents, often with anaerobic or mixed flora.

Epidemiology

Pneumonia remains a leading cause of morbidity and mortality worldwide, especially at the extremes of age and in patients with comorbid cardiopulmonary or immunocompromising conditions. CAP is one of the most common reasons for hospital admission and antibiotic prescription in adults, while HAP and VAP are major causes of hospital-acquired infection and are associated with higher rates of sepsis, acute respiratory distress syndrome (ARDS), and thromboembolic complications in settings such as COVID-19–associated pneumonia.^{[5](https://pubmed.ncbi.nlm.nih.gov/41461731/)}

Risk is increased in smokers, chronic lung disease, chronic heart, liver or kidney disease, diabetes, neurologic disease with impaired cough or swallowing, residence in long-term care facilities, recent hospitalization, and patients with indwelling devices or mechanical ventilation.

Pathophysiology

In pneumonia, pathogens reach the lower respiratory tract via microaspiration of oropharyngeal secretions, inhalation of aerosolized organisms, hematogenous spread, or direct extension from contiguous sites. Normal host defenses (mucociliary clearance, cough reflex, innate and adaptive immunity) are overcome by large inoculum, virulent organisms, or impaired host defenses.

The infection triggers an inflammatory response in the alveoli and interstitium. Neutrophils and macrophages migrate into the airspaces, leading to exudate formation and consolidation, impaired ventilation, reduced compliance, and ventilation–perfusion mismatch. In typical bacterial pneumonia (for example, Streptococcus pneumoniae), there is classically lobar consolidation, whereas atypical pathogens (for example, Mycoplasma, Chlamydophila, viruses) often produce more interstitial and patchy infiltrates rather than dense lobar involvement.

Systemic cytokine release results in fever, malaise, and in severe cases sepsis and multi-organ dysfunction. Complications include parapneumonic effusion and empyema, lung abscess, ARDS, and thromboembolic events, which have been highlighted in viral pneumonias such as COVID-19.^{[5](https://pubmed.ncbi.nlm.nih.gov/41461731/)}

Clinical Presentation

The presentation of pneumonia depends on the pathogen, severity, and host factors, but common features include respiratory and systemic symptoms.

• Typical bacterial pneumonia (e.g., pneumococcal CAP)
  • Acute onset fever, chills, rigors.
  • Productive cough with purulent or rust-colored sputum.
  • Pleuritic chest pain.
  • Dyspnea and tachypnea.
• Atypical pneumonia
  • More indolent onset, low-grade fever.
  • Dry or minimally productive cough.
  • Prominent extrapulmonary symptoms: headache, myalgias, sore throat, diarrhea.
• Viral pneumonia (including COVID-19)
  • Fever, dry cough, dyspnea, fatigue.
  • May be preceded by upper respiratory symptoms.
  • In severe cases, rapidly progressive hypoxemia and ARDS.
• Aspiration pneumonia
  • History of aspiration risk: altered consciousness, dysphagia, vomiting.
  • Cough, fever, dyspnea; often right lower lobe involvement.
  • Foul-smelling sputum can suggest anaerobes or lung abscess.

Physical examination may reveal:

• Fever, tachycardia, tachypnea, hypoxia.
• Use of accessory muscles or respiratory distress in severe disease.
• Localized dullness to percussion over consolidation.
• Decreased breath sounds, bronchial breath sounds, egophony, increased tactile fremitus.
• Crackles (rales) over affected areas.

Diagnosis

Diagnosis of pneumonia is based on compatible clinical features plus radiologic evidence of a new pulmonary infiltrate, with supportive laboratory and microbiologic data.

Initial Assessment and Risk Stratification

Initial assessment focuses on confirming pneumonia, estimating severity, identifying risk factors for multidrug-resistant organisms, and determining the appropriate site of care (outpatient vs inpatient vs ICU). Clinical prediction tools such as CURB-65 or the Pneumonia Severity Index (PSI) are commonly used to help estimate mortality risk and guide disposition decisions.

Laboratory Evaluation

• Basic labs: complete blood count (often leukocytosis with left shift, but leukopenia can occur in severe sepsis), serum electrolytes, renal and liver function, C-reactive protein and/or procalcitonin (sometimes used for severity and antibiotic stewardship).
• Arterial or venous blood gases: in hypoxemic or critically ill patients to assess gas exchange and acid–base status.
• Blood cultures: recommended for moderate to severe CAP, HAP/VAP, or when sepsis is suspected, prior to antibiotics whenever feasible.
• Sputum Gram stain and culture: ideally collected before antibiotics in hospitalized patients, especially with severe disease or risk for resistant pathogens.
• Viral testing: PCR-based respiratory viral panels, influenza and SARS-CoV-2 testing during relevant seasons or outbreaks; this is important for infection control and antiviral therapy decisions.^{[3](https://pubmed.ncbi.nlm.nih.gov/41626364/)}
• Special tests in selected cases: urinary antigens for Streptococcus pneumoniae and Legionella, serologic or PCR tests for atypical pathogens.

Imaging

• Chest radiograph (CXR) is the standard initial imaging test. Findings include lobar consolidation, patchy bronchopneumonia, or interstitial infiltrates. CXR helps differentiate pneumonia from other causes of respiratory symptoms (e.g., heart failure, pulmonary embolism).
• Chest CT is more sensitive than CXR and may be used when the diagnosis is uncertain, to evaluate complications such as abscess, empyema, or to evaluate nonresolving pneumonia.

Microbiology and Etiology

Etiology varies by setting and host. Common organisms include:

• CAP
  • Streptococcus pneumoniae – most common typical bacterial cause.
  • Viruses – influenza, respiratory syncytial virus (RSV), SARS-CoV-2; viral pneumonia has been associated with increased risk of complications such as thromboembolism in COVID-19.^{[5](https://pubmed.ncbi.nlm.nih.gov/41461731/)}
  • Atypical bacteria – Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila.
  • Haemophilus influenzae, Moraxella catarrhalis, Gram-negative bacilli, and Staphylococcus aureus (including MRSA) in certain patients.
• HAP/VAP
  • Gram-negative bacilli (e.g., Pseudomonas aeruginosa, Enterobacterales), Staphylococcus aureus (including MRSA), and multidrug-resistant organisms; risk is higher with prolonged hospitalization and prior antibiotic exposure.
• Aspiration pneumonia
  • Polymicrobial: oral anaerobes, mixed aerobic and anaerobic flora; Gram-negative bacilli and Staphylococcus aureus in institutionalized or hospitalized patients.

Management

Management of pneumonia includes prompt empiric antimicrobial therapy, supportive care, and addressing complications and comorbid conditions. Choice of therapy must account for severity, patient comorbidities, local resistance patterns, and risk factors for multidrug-resistant pathogens.

General Principles

• Start empiric antibiotics as soon as possible after the diagnosis is suspected, particularly in moderate to severe disease.
• Obtain cultures and diagnostic tests before antibiotics when feasible, without delaying therapy in unstable patients.
• Use guideline-concordant regimens and narrow spectrum based on culture results and clinical response.
• Assess daily for clinical stability and consider switching from IV to oral therapy when criteria are met.

Empiric Treatment – Community-Acquired Pneumonia (Adult, Nonpregnant)

Outpatient, no comorbidities and no risk factors for MRSA or Pseudomonas (specific agents and dosing may vary by guideline and local resistance patterns):

• High-dose amoxicillin, doxycycline, or a macrolide (if local pneumococcal macrolide resistance is low).

Outpatient with comorbidities (e.g., chronic heart, lung, liver, or kidney disease; diabetes; alcoholism; malignancy; asplenia):

• Combination therapy: amoxicillin–clavulanate or a cephalosporin (e.g., cefuroxime, cefpodoxime) plus a macrolide or doxycycline.
• Monotherapy: a respiratory fluoroquinolone (e.g., levofloxacin, moxifloxacin) as an alternative where appropriate.

Inpatient (non-ICU) CAP:

• IV beta-lactam (e.g., ceftriaxone, cefotaxime, ampicillin–sulbactam) plus a macrolide.
• Respiratory fluoroquinolone monotherapy is an alternative in some settings.

Severe CAP or ICU-level care (no risk factors for MRSA/Pseudomonas):

• IV beta-lactam plus macrolide, or beta-lactam plus respiratory fluoroquinolone.

Add MRSA or Pseudomonas coverage (e.g., vancomycin or linezolid for MRSA; antipseudomonal beta-lactam for Pseudomonas) if risk factors such as prior colonization/infection, recent hospitalization with IV antibiotics, or local epidemiology indicate increased risk.

Empiric Treatment – Hospital-Acquired and Ventilator-Associated Pneumonia

Regimens for HAP/VAP should be guided by local antibiograms and patient-specific risk factors for multidrug-resistant organisms. General approaches include:

• HAP without high risk of mortality or MDR pathogens: an antipseudomonal beta-lactam (e.g., piperacillin–tazobactam, cefepime, meropenem) alone, with MRSA coverage added if risk factors or high local prevalence.
• HAP/VAP with high risk of mortality or MDR: combination antipseudomonal therapy from two different classes plus MRSA coverage until culture data allow narrowing.

Duration is typically 7 days, modified based on clinical response and microbiology.

Management of Aspiration Pneumonia

• For community-onset aspiration pneumonia: regimens with anaerobic coverage such as amoxicillin–clavulanate; clindamycin is an alternative if beta-lactam allergy.
• For hospital-onset aspiration with risk for Gram-negative and MRSA: use broader-spectrum HAP/VAP regimens that also cover anaerobes when indicated.
• Lung abscess or empyema may require prolonged therapy and drainage procedures.

Supportive Care

• Oxygen therapy to maintain adequate saturation; escalation to high-flow oxygen, non-invasive ventilation, or mechanical ventilation in respiratory failure.
• Fluids and hemodynamic support in sepsis or shock; adherence to sepsis bundles when applicable.
• Antipyretics and analgesia for comfort.
• Bronchodilators for coexisting reactive airway disease or COPD.
• Thromboprophylaxis in hospitalized patients, particularly important in the setting of severe pneumonia and conditions like COVID-19 that increase thromboembolic risk.^{[5](https://pubmed.ncbi.nlm.nih.gov/41461731/)}

Prevention

Prevention strategies are essential to reduce pneumonia incidence and severity, especially in high-risk populations.

• Vaccination
  • Seasonal influenza vaccination reduces the risk of viral pneumonia and secondary bacterial infections; uptake in young adults such as university students remains suboptimal in some regions.^{[9](https://europepmc.org/article/MED/41787274)}
  • Pneumococcal vaccination (conjugate and polysaccharide vaccines) lowers the risk of invasive pneumococcal disease and pneumococcal pneumonia in older adults and high-risk groups.
• Respiratory hygiene: hand hygiene, cough etiquette, and use of masks in appropriate settings help limit transmission of respiratory pathogens identified via community and wastewater surveillance.^{[3](https://pubmed.ncbi.nlm.nih.gov/41626364/)}
• Smoking cessation to improve mucociliary clearance and immune function.
• Oral care and aspiration precautions in hospitalized, neurologically impaired, and ventilated patients.
• Infection control measures in healthcare settings to prevent HAP/VAP, including elevation of head of bed, minimizing sedation, early mobilization, and adherence to ventilator bundles.

Key Clinical Pearls and Exam Tips

• Diagnosis requires both symptoms/signs and imaging: respiratory symptoms plus focal findings on exam and a new infiltrate on CXR. Chronic or nonresolving opacities should prompt evaluation for malignancy, TB, or other causes.
• Distinguish typical vs atypical pneumonia patterns: high fever, lobar consolidation, and rust-colored sputum suggest pneumococcal pneumonia; indolent course with dry cough and extrapulmonary symptoms points toward atypical pathogens such as Mycoplasma.
• Always consider aspiration risk factors (stroke, seizures, alcohol intoxication, dysphagia) when pneumonia predominantly affects dependent lung segments, especially the right lower lobe.
• Use severity scores (CURB-65, PSI) to help determine site of care, but always interpret in clinical context.
• Early appropriate antibiotics improve outcomes; obtain cultures when indicated but do not delay therapy in unstable patients.
• Monitor for complications: parapneumonic effusion, empyema, lung abscess, ARDS, and thromboembolism, particularly in severe viral pneumonia such as COVID-19.^{[5](https://pubmed.ncbi.nlm.nih.gov/41461731/)}
• Vaccination and public health measures (including surveillance for respiratory pathogens via clinical and wastewater monitoring) are crucial components of pneumonia prevention strategies.^{[3](https://pubmed.ncbi.nlm.nih.gov/41626364/)}

Summary

Pneumonia is a common and potentially life-threatening infection of the lung parenchyma with diverse etiologies and presentations. For medical students, mastery of its definition, epidemiology, pathophysiology, clinical features, diagnostic approach, and evidence-based management is essential. Integrating risk stratification tools, appropriate empiric therapy, and preventive strategies such as vaccination will improve patient outcomes and is highly testable on examinations.